Download PDF
Diabetes aktuell 2016; 14(06): 294-298
DOI: 10.1055/s-0042-117665
Schwerpunkt
© Georg Thieme Verlag Stuttgart · New York

Fasten und Typ-2-Diabetes

Zunehmende Insulinresistenz und abnehmende Betazellfunktion des Pankreas sind umkehrbarFasting and type 2 diabetes - Increasing insulin resistance and decreasing betacell function of pancreatic tissue are reversable
Eva Lischka
1   Klinik Buchinger Wilhelmi am Bodensee, Überlingen
› Author Affiliations
Further Information

Publication History

Publication Date:
26 October 2016 (online)

Also available at
    Permissions and Reprints

Die Prävalenz des Typ-2-Diabetes in Deutschland beträgt annähernd 10 %. Eine kausale Therapie muss darauf abzielen, das viszerale Fett wieder seiner ursprünglichen und natürlichen Bestimmung zuzuführen - als Speicher für schlechte Zeiten, der regelmäßig wieder entleert wird. Die Fastentherapie nach Buchinger kann kombiniert mit Bewegung, Entspannung, den Ausgleich von Mikronährstoffmangel durch Aktivierung von Reparaturgenen und Autophagie sowohl zu einer oft lange anhaltenden Stoffwechselverbesserung führen als auch die notwendige Motivation zur Lebensstiländerung erzeugen.

The prevalence of type 2 diabetes in Germany is nearly 10 %. A causal therapy should aim at using the visceral fat again for its initial and natural purpose as a reservoir for bad times, which is emptied regularly. In combination with physical activity, relaxation, compensation for a micronutrient deficiency by activation of repair genes and autophagy, the fasting therapy according to Buchinger can lead to a long lasting improvement of the metabolism and can create the necessary motivation for changing one’s lifestyle.

Key words

fasting therapy according to Buchinger - type 2 diabetes - autophagy - mitohormesis - change of lifestyle
 

  • Literatur

  • 1 Wilhelmi de Toledo F, Buchinger A, Burggrabe H et al. Leitlinien zur Fastentherapie. Forsch Komplementärmed Klass Naturheilkd 2002; 9: 189-198
    CrossrefGoogle Scholar
  • 2 Fahrner H. Fasten als Therapie: Buchinger Heilfasten. Stuttgart: Hippokrates; 1985
    Google Scholar
  • 3 Norrelund H, Sreekumaran Nair K, Lunde Jørgensen JO et al. The proteine-retaining effects of growth hormon during fasting involve inhibition of muscle-proteine break down. Diabetes 2001; 50: 96-104
    CrossrefGoogle Scholar
  • 4 Lim EL, Hollingsworth KG, Aribisala BS et al. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreasedpancreas and liver triacylglycerol. Diabetologia 2011; 54: 2506-2514
    CrossrefGoogle Scholar
  • 5 Stange R. Fasting therapy improves insulin resistance (HOMA-IR) in patients with the metabolicsyndrome. In: Abstract: North American ResearchConference on Complementary and Integrative Medicine; Edmonton, CA: 2006: 34
    Google Scholar
  • 6 Longo VD, Mattson MP. Fasting: molecular mechanisms and clinical applications. Cell Metab 2014; 19: 181-192
    CrossrefGoogle Scholar
  • 7 Michalsen A, Li C. Fasting therapy for treating and preventing disease – current state of evidence. Forsch Komplementmed 2013; 20: 444-453
    CrossrefGoogle Scholar
  • 8 Michalsen A, Hoffmann B, Moebus S et al. Incorporation of fasting therapy in an integrative medicine ward: evaluation of outcome, safety, and effects on lifestyle adherence in a large prospective cohort study. J Altern Complement Med 2005; 1: 601-607
    Google Scholar
  • 9 Huether G, Zhou D, Schmidt S et al. Long-term food restriction down-regulates the density of serotonin transporters in the rat frontal cortex. Biol Psychiatry 1997; 41: 1174-1180
    CrossrefGoogle Scholar
  • 10 Hatori M, Vollmers C, Zarrinpar A et al. Time-restricted feeding without reducing caloric intake prevents metabolic diseases in mice fed a high-fat diet. Cell Metab 2012; 15: 848-860
    CrossrefPubMedGoogle Scholar